🕵️ Keros Therapeutics, Inc. ($KROS)
SEC insider & ownership activity, last 12 months · CIK 1664710 · every row links its SEC filing
Over the last 12 months insiders sold $181.1M against $66K of open-market buying. ADAR1 Capital Management, LLC sold $95.7M in discretionary trades (Oct). No red-flag 8-Ks in the window.
🚨 1 signal active —
planned-vs-executed verdicts, pre-event flags, and cluster context live in the
API and the
alerts bot.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
1 buyer, $66K (5 lots) · 10 sellers, $181.1M (15 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 0 | – | 3 | $95.7M | Oct 15, 2025 |
| Pontifax Management 4 GP (2015) Ltd. | 0 | – | 4 | $85.0M | Oct 15, 2025 |
| Seehra Jasbir | 0 | – | 1 | $113K | Feb 19, 2026 |
| Cho Esther | 0 | – | 1 | $78K | Feb 18, 2026 |
| Regnante Keith | 0 | – | 1 | $77K | Feb 18, 2026 |
| Bienaime Jean Jacques | 5 | $66K | 0 | – | Jul 15, 2026 |
| Lerner Lorena Raquel | 0 | – | 1 | $63K | Feb 18, 2026 |
| Farzan Nima | 0 | – | 1 | $28K | Jun 4, 2026 |
| Knowles Julius | 0 | – | 1 | $28K | Jun 4, 2026 |
| Seth Alpna | 0 | – | 1 | $28K | Jun 4, 2026 |
| Charles W. Newton | 0 | – | 1 | $6K | Jun 11, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Blackrock, Inc. | 8.4% | 13G | Jul 29, 2026 | filing ↗ | |
| Nantahala Capital Management, LLC | 6.9% | 13G | May 15, 2026 | filing ↗ | |
| Wilmot B. Harkey | 6.9% | 13G | May 15, 2026 | filing ↗ | |
| Daniel Mack | 6.9% | 13G | May 15, 2026 | filing ↗ | |
| Blackrock Portfolio Management LLC | 5.7% | 13G | Jul 17, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Charles W. Newton | $5K | Jun 11, 2026 | filing ↗ |
| Farzan Nima | $28K | Jun 4, 2026 | filing ↗ |
| Knowles Julius | $28K | Jun 4, 2026 | filing ↗ |
| Seth Alpna | $28K | Jun 4, 2026 | filing ↗ |
| Orbimed Genesis Master Fund, LP | $497K | Mar 31, 2026 | filing ↗ |
| Rovaldi Christopher | $1.3M | Sep 12, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Jul 17, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 23, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 23, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 23, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 3, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jun 1, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 1, 2026 | filing ↗ |
| Earnings (2.02) | May 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 14, 2026 | filing ↗ |
| Other events (8.01) | Mar 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 9, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 4, 2026 | filing ↗ |
| Earnings (2.02) | Mar 4, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 4, 2026 | filing ↗ |
| Officer/director changes (5.02) | Feb 20, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 20, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 20, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Feb 18, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 18, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 9, 2026 | filing ↗ |
| Earnings (2.02) | Nov 5, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 5, 2025 | filing ↗ |
| Material agreement (1.01) | Oct 15, 2025 | filing ↗ |
| Earnings (2.02) | Oct 15, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 15, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Oct 15, 2025 | filing ↗ |
| Other events (8.01) | Oct 15, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Oct 15, 2025 | filing ↗ |